Drug Discovery

Genetic mapping of 10,000 Singaporeans reveals that nearly every citizen carries at least one genetic variant that negatively interacts with specific prescription medications. This startling statistic underscores a fundamental flaw in the traditional "one-size-fits-all" model of medicine, which has

Vensobafusp alfa seeks to redefine renal therapy by employing a bifunctional fusion protein that targets both the terminal and alternative complement pathways. For patients living with IgA nephropathy, the persistent threat of progressing toward end-stage renal disease remains a daunting reality

Phase I clinical trials are currently evaluating the safety and efficacy of BI 1703880 in human patients with advanced solid tumors following successful preclinical validations. This breakthrough comes at a pivotal moment in oncology, as researchers strive to solve the disconnect between localized

The pursuit of a definitive cure for solid tumors has long been hindered by a biological paradox where the very therapies designed to annihilate malignant cells often end up inflicting severe damage on healthy tissues. This persistent struggle with toxicity has left many promising immunotherapies

The nomination of ISM9546 marks a significant milestone for generative artificial intelligence, demonstrating its capacity to solve multi-parameter optimization challenges in complex autoimmune research. For decades, the pharmaceutical industry has grappled with the high failure rates of

A massive capital infusion from Sixth Street Partners, which added over 846,000 shares, signals a strong bet on the next phase of Regeneron’s medical pipeline. This institutional confidence arrives as the biotechnology giant demonstrates remarkable clinical prowess, particularly with its latest